Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 28 Jun 2018 New trial record